Raymond James & Associates Grows Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Raymond James & Associates raised its stake in Blueprint Medicines Co. (NASDAQ:BPMCGet Rating) by 8.8% in the 3rd quarter, Holdings Channel.com reports. The firm owned 31,433 shares of the biotechnology company’s stock after acquiring an additional 2,551 shares during the period. Raymond James & Associates’ holdings in Blueprint Medicines were worth $2,071,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. increased its position in shares of Blueprint Medicines by 7.8% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 44,186 shares of the biotechnology company’s stock worth $2,911,000 after purchasing an additional 3,211 shares during the last quarter. Xponance Inc. bought a new stake in shares of Blueprint Medicines in the 3rd quarter worth about $222,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Blueprint Medicines in the 3rd quarter worth about $37,000. Moody Aldrich Partners LLC bought a new stake in shares of Blueprint Medicines in the 3rd quarter worth about $1,198,000. Finally, Mackenzie Financial Corp increased its position in shares of Blueprint Medicines by 36.9% in the 3rd quarter. Mackenzie Financial Corp now owns 5,796 shares of the biotechnology company’s stock worth $382,000 after purchasing an additional 1,561 shares during the last quarter.

Blueprint Medicines Trading Up 0.6 %

Blueprint Medicines stock opened at $46.69 on Monday. The company has a quick ratio of 6.79, a current ratio of 6.99 and a debt-to-equity ratio of 0.19. The firm has a 50-day moving average price of $45.50 and a two-hundred day moving average price of $55.18. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of -3.86 and a beta of 0.64. Blueprint Medicines Co. has a 52-week low of $40.78 and a 52-week high of $85.67.

Blueprint Medicines (NASDAQ:BPMCGet Rating) last posted its earnings results on Tuesday, November 1st. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.51) by $0.28. Blueprint Medicines had a negative net margin of 263.54% and a negative return on equity of 56.45%. The firm had revenue of $65.98 million during the quarter, compared to analyst estimates of $43.49 million. Sell-side analysts expect that Blueprint Medicines Co. will post -9.38 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Kate Haviland purchased 1,100 shares of the company’s stock in a transaction on Thursday, November 3rd. The shares were bought at an average cost of $43.98 per share, for a total transaction of $48,378.00. Following the transaction, the chief executive officer now owns 92,281 shares of the company’s stock, valued at $4,058,518.38. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Kate Haviland purchased 1,100 shares of the company’s stock in a transaction on Thursday, November 3rd. The shares were bought at an average cost of $43.98 per share, for a total transaction of $48,378.00. Following the transaction, the chief executive officer now owns 92,281 shares of the company’s stock, valued at $4,058,518.38. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey W. Albers sold 20,000 shares of the business’s stock in a transaction dated Monday, December 5th. The stock was sold at an average price of $50.09, for a total transaction of $1,001,800.00. Following the sale, the director now owns 183,243 shares in the company, valued at $9,178,641.87. The disclosure for this sale can be found here. 3.42% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BPMC. Jefferies Financial Group dropped their target price on shares of Blueprint Medicines from $84.00 to $80.00 in a research report on Wednesday, November 2nd. Oppenheimer lowered shares of Blueprint Medicines from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 2nd. Wedbush decreased their price target on shares of Blueprint Medicines from $120.00 to $106.00 and set an “outperform” rating for the company in a report on Wednesday, November 2nd. HC Wainwright decreased their price target on shares of Blueprint Medicines from $80.00 to $70.00 and set a “buy” rating for the company in a report on Wednesday, November 2nd. Finally, SVB Leerink decreased their price target on shares of Blueprint Medicines from $57.00 to $52.00 and set a “market perform” rating for the company in a report on Wednesday, November 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $80.00.

About Blueprint Medicines

(Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

Featured Articles

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. (NASDAQ:BPMCGet Rating).

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.